天美传媒

artios header image

News & Events

Artios Announces Clinical Trial Collaboration with GSK to Evaluate Alnodesertib in Combination with Risvutatug Rezetecan, a B7-H3-Targeted ADC in Gastrointestinal Tumors

12 May 2026 | Press release

Blog-6

Artios Further Expands Leadership Team to Advance Oncology Pipeline and Accelerate Regulatory Execution

4 May 2026 | Press release

Blog-6

Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer

2 March 2026 | Press release

Blog-6

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Pol胃) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer

23 February 2026 | Press release

Blog-6

Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline

16 February 2026 | Press release

Blog-6

Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference

7 January 2026 | Press release

Blog-6

Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need

17 November 2025 | Press release

Blog-6

Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025

17 October 2025 | Press release

Blog-6

Artios to Announce First Phase 1/2a Data for DNA Polymerase Theta (Pol胃) Inhibitor ART6043 in Advanced Solid Tumors in Oral Presentation at ESMO

13 October 2025 | Press release

Blog-6

Artios Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC)

24 September 2025 | Press release

Blog-6

1 2 3 4 Next »

© Artios Pharma 天美传媒 2026 | 天美传媒

Terms & conditions | Privacy policy | Site map